Induction Chemotherapy Followed by Chemo-intensity-modulated Radiotherapy for Locally Advanced Nasopharyngeal Cancer

Clinical Oncology

Volumn 28, Issue 8, 2016, Pages e61-e67

  Miah, A B ^a,b   Bhide, S A ^a,b   Del Rosario, L ^a   Matthews, J ^a   Nicol, R ^a   Tanay, M A ^a   Gupta, S ^a   Zaidi, S H ^a   Newbold, K L ^a,b   Harrington, K J ^a,b   Nutting, C M ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Chemoradiotherapy; IMRT; nasopharyngeal cancer; radiotherapy; sequential

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL;

ACUTE TOXICITY; ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DYSPHAGIA; FATIGUE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INDUCTION CHEMOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; KIDNEY DYSFUNCTION; LOCAL RECURRENCE FREE SURVIVAL; LONGITUDINAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CANCER; NEUTROPENIA; OTOTOXICITY; OVERALL SURVIVAL; PAIN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIATION DOSE FRACTIONATION; SEPSIS; TINNITUS; TREATMENT OUTCOME; XEROSTOMIA; ADVERSE EFFECTS; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; NASOPHARYNGEAL NEOPLASMS; PROCEDURES;

ADULT; AGED; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84971467917     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2016.01.012     Document Type: Article

References (22)

1. [1] Chan, A.T., Gregoire, V., Lefebvre, J.L., et al. Nasopharyngeal cancer: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:Suppl. 5 (2010), v187–189.
2. [2] National Cancer Intelligence Network, Incidence and mortality from head and neck cancers in England. 2002–2006.
3. [3] Pow, E.H., Kwong, D.L., McMillan, A.S., et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 66 (2006), 981–991.
4. [4] Kam, M.K., Leung, S.F., Zee, B., et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 25 (2007), 4873–4879.
5. [5] American Joint Committee on Cancer, Manual for staging of cancer. 5th edn, 1997.
6. [6] Cox, J.D., Stetz, J., Pajak, T.F., Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995), 1341–1346.
7. [7] Nutting, C.M., Morden, J.P., Harrington, K.J., et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 12 (2011), 127–136.
8. [8] National Institute of Health. Common Terminology Criteria for Adverse Events v3.0.
9. [9] Rubin, P., Constine, L.S. 3rd, Fajardo, L.F., et al. EORTC Late Effects Working Group. Overview of late effects normal tissues (LENT) scoring system. Radiother Oncol 35 (1995), 9–10.
10. [10] Bentzen, S.M., Radiobiological considerations in the design of clinical trials. Radiother Oncol 32 (1994), 1–11.
11. [11] Colaco, R.J., Betts, G., Donne, A., et al. Nasopharyngeal carcinoma: a retrospective review of demographics, treatment and patient outcome in a single centre. Clin Oncol (R Coll Radiol) 25:3 (2013 Mar), 171–177.
12. [12] Lee, N., Xia, P., Quivey, J.M., et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 53:1 (2002), 12–22.
13. [13] Zhao, L.N., Zhou, B., Shi, M., et al. Clinical outcome for nasopharyngeal carcinoma with predominantly WHO II histology treated with intensity-modulated radiation therapy in non-endemic region of China. Oral Oncol 48:9 (2012 Sep), 864–869.
14. [14] Wu, Z., Zeng, R.F., Su, Y., et al. Prognostic significance of tumor volume in patients with nasopharyngeal carcinoma undergoing intensity-modulated radiation therapy. Head Neck 35:5 (2013 May), 689–694.
15. [15] Gulliford, S.L., Miah, A.B., Brennan, S., et al. Dosimetric explanations of fatigue in head and neck radiotherapy: an analysis from the PARSPORT phase III trial. Radiother Oncol 104 (2012), 205–212.
16. [16] Powell, C., Schick, U., Morden, J.P., et al. Fatigue during chemoradiotherapy for nasopharyngeal cancer and its relationship to radiation dose distribution in the brain. Radiother Oncol 110 (2014), 416–421.
17. [17] Lee, A.W., Nasopharyngeal cancer: advances in radiotherapy. Int J Radiat Oncol Biol Phys 69 (2007), S115–S117.
18. [18] Bhide, S.A., Harrington, K.J., Nutting, C.M., Otological toxicity after postoperative radiotherapy for parotid tumours. Clin Oncol (R Coll Radiol) 19 (2007), 77–82.
19. [19] Wolden, S.L., Chen, W.C., Pfister, D.G., et al. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys 64:1 (2006), 57–62.
20. [20] Kwong, D.L., Sham, J.S., Leung, L.H., et al. Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 64:2 (2006), 374–381.
21. [21] Kam, M.K., Teo, P.M., Chau, R.M., et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. Int J Radiat Oncol Biol Phys 60:5 (2004), 1440–1450.
22. [22] Lin, S., Lu, J.J., Han, L., et al. Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: experience of 370 consecutive cases. BMC Cancer, 10, 2010, 39.